Royalty Pharma plc
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Dec 2017 | — | $4.46B | $1.38B |
| Dec 2018 | — | $4.55B | $1.92B |
| Mar 2019 | — | $4.71B | — |
| Jun 2019 | — | $4.65B | $593.3M |
| Sep 2019 | — | $4.90B | $116.4M |
| Dec 2019 | $5.96B | $6.14B | $246.2M |
| Mar 2020 | — | $7.16B | $498.1M |
| Jun 2020 | $5.73B | $9.39B | $2.44B |
| Sep 2020 | $5.81B | $9.80B | $1.55B |
| Dec 2020 | $5.82B | $9.90B | $1.01B |
| Mar 2021 | $5.82B | $9.84B | $708.8M |
| Jun 2021 | $5.83B | $10.41B | $1.14B |
| Sep 2021 | $7.09B | $10.39B | $1.80B |
| Dec 2021 | $7.10B | $10.25B | $1.54B |
| Mar 2022 | $7.10B | $10.14B | $1.79B |
| Jun 2022 | $7.11B | $10.41B | $2.11B |
| Sep 2022 | $6.11B | $10.42B | $991.6M |
| Dec 2022 | $6.12B | $9.53B | $1.71B |
| Mar 2023 | $6.12B | $9.82B | $1.98B |
| Jun 2023 | $6.13B | $9.81B | $2.17B |
| Sep 2023 | $6.13B | $9.59B | $936.4M |
| Dec 2023 | $6.14B | $10.08B | $477.0M |
| Mar 2024 | $6.14B | $9.86B | $843.0M |
| Jun 2024 | $7.60B | $9.75B | $1.76B |
| Sep 2024 | $6.61B | $10.26B | $950.1M |
| Dec 2024 | $6.61B | $10.34B | $929.0M |
| Mar 2025 | $6.62B | $9.78B | $1.09B |
| Jun 2025 | $7.00B | $9.49B | $631.9M |
| Sep 2025 | $8.57B | $9.62B | $938.9M |
| Dec 2025 | $8.57B | $9.71B | $618.7M |
| Mar 2026 | $8.58B | $9.94B | $586.4M |
| Jun 2026 | $8.58B | $9.79B | $812.0M |